Indiatimes on MSN6d
Should you rethink laser treatment for your varicose veins?
Varicose veins require thorough assessment by vascular surgeons, especially using ultrasound, to determine the underlying ...
MedPage Today1d
FDA OKs Bioengineered Vessel to Reduce Limb Amputations After Vascular Trauma
The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular ...
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...
FDA approval propels North Carolina company's breakthrough treatment for trauma patients
A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...
Monthly Prescribing Reference1d
Symvess, a Novel Treatment for Vascular Trauma, Gets FDA Approval
The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.
Does Medicare Cover Varicose Vein Treatment?
Seeking treatment for those bulging, sometimes painful veins that pop up more often as you age? Here's what to know about ...
Daily Excelsior13d
Understanding Varicose Veins: Symptoms, Causes, and When to Seek Medical Help
Varicose veins are a medical condition that affects more than thirty percent of the general population in India. Varicose ...
Endovascular Today1d
Humacyte’s Symvess ATEV Approved by FDA for Treatment of Extremity Vascular Trauma
Humacyte, Inc. announced that the FDA has granted full approval for the company’s Symvess—acellular tissue enginee ...
Seacoastonline.com10d
Health care professionals: Names to Know
YORK, Maine — York Hospital announced the expansion of its vascular and vein care services, with the addition of a new team ...
bovnews2d
A Biotech Breakthrough: Humacyte’s (HUMA) Game-Changing FDA Approval Sends Stock Soaring
As of Friday’s premarket trading session, Humacyte’s stock surged +33.52% to $4.62, reflecting investor optimism following this groundbreaking news. While the company’s stock has had a solid +21.83% ...